3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
4
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Classical hematology
2
Tumor-Agnostic
1
Conditions
Neoplasms
1
Anemia, Iron-Deficiency
1
Anemia
1
Interventions
fludarabine phosphate
58
Cyclophosphamide
54
Epoetin Alfa
43
Cyclosporine
43
Busulfan
43
Peripheral Blood Stem Cell Transplantation
39
Mycophenolic Acid
34
Darbepoetin alfa
33
Antilymphocyte Serum
31
Whole-Body Irradiation
30
Cytarabine
30
Filgrastim
29
Methotrexate
26
Tacrolimus
25
Radiotherapy
25
Melphalan
24
fludarabine
21
Methylprednisolone
17
Cord Blood Stem Cell Transplantation
17
Etoposide
14
Granulocyte Colony-Stimulating Factor
13
Daunorubicin
13
Rivaroxaban
12
apixaban
11
Thiotepa
11
sargramostim
10
epoetin beta
10
Dalteparin
10
eltrombopag
9
Alemtuzumab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
iron isomaltoside 1000
×
Classical hematology
×
Clear all
NCT04318405
2023-07-19
Real-CHOICE
Pierre Fabre Pharma AG
Completed
327 enrolled
NCT01280240
2013-06-04
PK-CIA-06
Pharmacosmos A/S
Phase 1
Completed
11 enrolled